Global Health Innovative Technology Fund

CFI Launches 'Khubara Al Najah' Podcast with Mustafa Al Agha

Retrieved on:

Friday, June 9, 2023

Celebrity, CFI, Failure, Habit, Cuban success story, Podcast, Entrepreneurship, Motivation, Apple, Global Health Innovative Technology Fund, Knowledge, Arab world, Empowerment, Spotify

The podcast features the legendary sports journalist and media personality, Mustafa Al-Agha, along with CFI board member and an accomplished businessman, Ahmad Khatib, as its hosts.

Key Points:

The podcast features the legendary sports journalist and media personality, Mustafa Al-Agha, along with CFI board member and an accomplished businessman, Ahmad Khatib, as its hosts.
Both hosts share empowering discussions with exciting guests across this 12-episode podcast series, starting with His Excellency Fahad Al Gergawi, CEO of Dubai Investment Development Agency, in Episode 1 - "Principles of Investment with His Excellency Fahad Al Gergawi."
For those looking for practical advice and inspiration to reach their financial goals, Khubara Al Najah is the podcast you cannot miss.
That's why we chose the podcast medium to pique the interest of astute individuals.

Government of Japan Expresses its Pledge of US$200 Million to GHIT Fund/UNDP Replenishment

Retrieved on:

Thursday, May 25, 2023

TOKYO, May 25, 2023 /PRNewswire/ -- At the G7 Hiroshima Summit 2023, Prime Minister Fumio Kishida announced the Government of Japan's pledge to contribute US$200 million to the Global Health Innovative Technology Fund (GHIT Fund)/United Nations Development Programme (UNDP). This pledge supports the GHIT Fund's third phase of operations, including investments in research and development (R&D) of drugs, vaccines and diagnostics, utilizing Japan's innovation and expertise to prevent and address infectious diseases such as tuberculosis, malaria and neglected tropical diseases (NTDs), which are highly prevalent in low- and middle-income countries.

Key Points:

In addition to the new contribution from the Government of Japan, support from industry for GHIT's replenishment has increased compared to previous replenishments.
Additionally, founding foundation partners Bill & Melinda Gates Foundation and Wellcome will continue to support GHIT.
Over the next five years, the GHIT Fund will strive to secure additional support with a total replenishment goal of US$400 million to support operations and investments.
This replenishment supports the implementation of "GHIT 3.0," the institution's third five-year plan, as follows.

GHIT Fund Secures USD 24 Million Pledge From Bill & Melinda Gates Foundation Over Three Years

Retrieved on:

Wednesday, May 10, 2023

"The Bill & Melinda Gates Foundation has been supporting the GHIT Fund as a critical partner since its inception.

Key Points:

"The Bill & Melinda Gates Foundation has been supporting the GHIT Fund as a critical partner since its inception.
Katey Owen, director of neglected tropical diseases and director, vaccine development, Bill & Melinda Gates Foundation, said: "Over the past nine years, our relationship with GHIT has evolved and expanded.
The GHIT Fund is a Japan-based international public-private partnership fund (PPP) that was formed between the Government of Japan, multiple pharmaceutical companies, the Bill & Melinda Gates Foundation, Wellcome, and the United Nations Development Programme (UNDP).
The Bill & Melinda Gates Foundation is a US-based foundation established in 2000.

Vizient Innovative Technology Contract Awarded to Fresenius Kabi for the Ivenix Infusion System

Retrieved on:

Monday, April 17, 2023

Medical Devices, Health, Hospitals, Health Technology, General Health, Biotechnology, Information, Fresenius (company), AUC, Global Health Innovative Technology Fund, Zenith Contract Services, Hospital, Patient, Patient safety, Nursing, Medical device, Vizient, Inc.

Fresenius Kabi announced today its Ivenix Infusion System has received an Innovative Technology contract from Vizient, Inc. the nation's largest member-driven health care performance improvement company.

Key Points:

Fresenius Kabi announced today its Ivenix Infusion System has received an Innovative Technology contract from Vizient, Inc. the nation's largest member-driven health care performance improvement company.
Innovative Technology contracts are recommended after review and interaction with products submitted through Vizient's Innovative Technology Program.
The contract sets terms for hospitals to evaluate and purchase the Ivenix Infusion System, an advanced and user-friendly infusion pump system.
“We are thrilled to be awarded an Innovative Technology contract from Vizient for the Ivenix Infusion System,” said Christian Hauer, Executive Board Member and President of Fresenius Kabi MedTech.

PointClickCare Demonstrates Cross-Continuum Care Collaboration at HIMSS23

Retrieved on:

Monday, April 17, 2023

PointClickCare is focused on transforming the healthcare ecosystem through a connected care network powered by insights with a commitment to driving value, outcomes, and innovation.

Key Points:

PointClickCare is focused on transforming the healthcare ecosystem through a connected care network powered by insights with a commitment to driving value, outcomes, and innovation.
The company is uniquely positioned to support its customers in data sharing efforts across the care continuum, as well as enabling better transitions of care and deeper collaboration.
“Our team is dedicated to designing secure solutions that enable improved quality and efficiency of care, and allow for true collaboration across the healthcare ecosystem,” said BJ Boyle , Chief Product Officer at PointClickCare.
Visit PointClickCare on the show floor at booth #7206 or schedule time to connect with us to learn more: https://pointclickcare.com/campaign/himss-2023-chicago/ .

OpGen’s Subsidiary Curetis Signs Expansion of R&D Collaboration with FIND

Retrieved on:

Wednesday, April 5, 2023

Partnership, Antimicrobial stewardship, DNA sequencing, Infection, Research, Global Health Innovative Technology Fund, IP, LMIC, Patient, Medicine, Medical device

The work already completed under the collaboration will be expanded by three work packages increasing total project volume to up to € 830 thousand in revenue potential.

Key Points:

The work already completed under the collaboration will be expanded by three work packages increasing total project volume to up to € 830 thousand in revenue potential.
The added deliverables will address the following topics:
An Antimicrobial Stewardship Module supporting users with rule-based information to allow making the best treatment choices based on respective hospital’s drug availability;
Next Generation Sequencing (“NGS”) strain analysis including isolates from several sub-Saharan African countries to investigate any potential sequence differences.
Dr. Gerd Luedke, Director Innovation, Technology and IP at OpGen’s German subsidiary Curetis GmbH commented: “As we approach the final milestones from the original first phase of our collaboration agreement, we are excited to expand the scope of our R&D partnership with FIND.
It will help our team to better evaluate the potential of Unyvero A30 to help identify blood stream infections in patients admitted to LMIC hospitals.”

OpGen’s Subsidiary Curetis Meets Milestones in Collaborative Research Project with InfectoGnostics

Retrieved on:

Monday, April 3, 2023

The InfectoGnostics Research Campus Jena is a public-private partnership breaking new ground in the diagnosis of infections.

Key Points:

The InfectoGnostics Research Campus Jena is a public-private partnership breaking new ground in the diagnosis of infections.
The Ares team applied its unique machine learning (ML) and AI capabilities to support the research project.
Dr. Gerd Luedke, Director Innovation, Technology and IP at OpGen’s subsidiary Curetis commented: “We are excited to complete several key milestones in this joint research collaboration.
This success could open up the potential for additional collaborative work being conducted under the PREPLEX project which could provide additional funding of a few hundred thousand dollars to OpGen’s Curetis research team in the coming years.”

A Total of Approximately 400 Million Yen Investment in Eisai, Ehime University, DNDi and Others for New Drug and Vaccine Development for Neglected Tropical Diseases

Retrieved on:

Thursday, March 30, 2023

The GHIT Fund will invest approximately 300 million yen (US$2.2 million1) in a project by Eisai Co., Ltd. (Eisai) and Drugs for Neglected Diseases initiative (DNDi) for regulatory approval and to prepare for patient access to drugs for eumycetoma.

Key Points:

The GHIT Fund will invest approximately 300 million yen (US$2.2 million1) in a project by Eisai Co., Ltd. (Eisai) and Drugs for Neglected Diseases initiative (DNDi) for regulatory approval and to prepare for patient access to drugs for eumycetoma.
Mycetoma, an NTD, is a progressive disease that destroys subcutaneous and deep tissues infected by bacterial or fungal invasion through a wound.
We hope this treatment will be quickly approved and reach patients as soon as possible, during GHIT's third five-year plan."
The GHIT Fund invests and manages an R&D portfolio of development partnerships aimed at neglected diseases, such as malaria, tuberculosis and neglected tropical diseases that afflict the world's vulnerable and underserved populations.

The Alpha Blue Ocean Group announces a new line of financing worth €29.9 million with SAFE

Retrieved on:

Friday, March 24, 2023

Professional Services, Health, Business, Surgery, Health Technology, Finance, Consulting, Marketing, Interview, Ticker, ABO, Global Health Innovative Technology Fund, Innovation, SAFE, Loyal, Renewable energy

Alpha Blue Ocean (ABO), the family office founded by Pierre Vannineuse, is proud to announce a new line of financing from one of its long-term partners, SAFE Group, to support its growth trajectory.

Key Points:

Alpha Blue Ocean (ABO), the family office founded by Pierre Vannineuse, is proud to announce a new line of financing from one of its long-term partners, SAFE Group, to support its growth trajectory.
Loyal to its objective of forging ties with its long-term partners, such as SAFE, the Alpha Blue Ocean Group is proud to announce a new line of financing worth up to €29.9 million.
In five years, the group founded by Pierre Vannineuse has deployed over €2 billion, 60% of which has been invested in the Health & Innovation segments.
For any further information or requests for an interview with a manager at Alpha Blue Ocean, please contact the press department: [email protected]

Firstboard.io® Announces Partner Network and Founding Partners Working to Increase Women on Tech Boards

Retrieved on:

Thursday, March 16, 2023

SAN FRANCISCO, March 16, 2023 /PRNewswire-PRWeb/ -- The representation of women in the tech industry still hovers at less than 30% and in the boardrooms of privately held companies the number of female board members is much lower. Only 14% of board director seats for private companies are held by women, and 56% of early-stage private companies had zero-woman directors, according to a 2022 report by the Women Business Collaborative in partnership with 50/50 Women on Boards.

Key Points:

Harnessing the support of industry leaders from the tech industry to increase the representation of women on private company boards.
Firstboard.io®, a curated network of highly qualified and diverse technology leaders, announced today the launch of its Partner Network and its Founding Partners working to support the organization's efforts and increase the representation of women in the boardrooms of private companies.
"Working with our partners we want to make visible for consideration highly qualified women ready to serve on boards. "
Firstboard.io invites corporate partners who want to support efforts to increase the representation of women on private company boards to contact Firstboard.io and join the Partner Network.